NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
The 2018 Annual Meeting of Stockholders of NewLink Genetics Corporation (the "Company") was held on May 23, 2018, for the following purposes:
|
To elect the nominees for director, Chad A. Johnson, Ernest J. Talarico, III and Lota S. Zoth, nominated by the Board of Directors of the Company (the "Board"), to serve until the 2021 Annual Meeting of Stockholders; |
|
To approve, on an advisory basis, the compensation of the Company's named executive officers; |
|
To approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers; and |
|
To ratify the selection by the Audit Committee of the Board of KPMG, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. |
At the meeting, Ernest J. Talarico, III and Lota S. Zoth were re-elected as directors of the Company and Chad A. Johnson was elected as a director of the Company. The stockholders of the Company approved, on an advisory basis, the compensation of the Company's named executive officers, as set forth in the Company's definitive proxy statement, filed with the Securities and Exchange Commission on April 9, 2018. The stockholders of the Company approved, on an advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers with a frequency of every one year. In addition, the stockholders of the Company ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2018. The final voting results on each of the matters submitted to a vote of stockholders at the 2018 Annual Meeting are as follows:
|
Election of Directors |
For |
Withheld |
Broker Non-Votes |
|
|
1. |
Chad A. Johnson |
21,853,989 |
260,602 |
11,650,471 |
|
Ernest J. Talarico, III |
21,776,165 |
338,426 |
11,650,471 |
|
|
Lota S. Zoth |
18,352,927 |
3,761,664 |
11,650,471 |
|
For |
Against |
Abstentions |
Broker Non-Votes |
||
|
2. |
Approval, on an advisory basis, of the compensation of the Company's named executive officers |
21,576,390 |
433,129 |
105,072 |
11,650,471 |
|
1 Year |
2 Years |
3 Years |
Abstentions |
Broker Non-Votes |
||
|
3. |
Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers |
21,853,598 |
25,025 |
192,448 |
43,520 |
11,650,471 |
|
For |
Against |
Abstentions |
||
|
4. |
Ratification of KPMG LLP as independent registered public accounting firm for the Company's fiscal year ending December 31, 2018 |
33,493,670 |
159,374 |
112,018 |
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
